Author(s):
Molecular glues represent a powerful approach in targeted protein degradation, inducing new interactions between target proteins and E3 ligases, leading to proteasomal destruction. This strategy effectively addresses previously undruggable targets and offers significant promise in cancer and neurodegenerative diseases. The field is evolving from serendipitous discoveries to rational design, aided by computational methods and structural insights. Expanding beyond traditional E3 ligases like Cereblon (CRBN) and Von Hippel-Lindau (VHL) is crucial for broadening therapeutic applications and overcoming resistance, marking a significant advancement in drug discovery.
